December 29 news, traditional Chinese medicine stocks continue to be active, as of press time, essence Pharmaceutical 4-board, Watson Pharmaceutical rose, Tai long Pharmaceutical, Yabao Pharmaceutical, Foci Pharmaceutical followed.
On the news side, recently, the prices of proprietary Chinese medicines in several well-known domestic pharmaceutical companies have increased by 10% to 20%, including some common varieties. Affected by this, the Chinese medicine plate continues to heat up recently. Industry insiders said that the rise in the price of proprietary Chinese medicine is mainly due to the rise in the price of traditional Chinese medicine. Brokerage analysis believes that under the policy support and the catalysis of price increase, traditional Chinese medicine enterprises with low valuation and strong brand influence have been paid attention to. In the past two years, a number of incentive policies have been issued, the traditional Chinese medicine industry has ushered in new opportunities for development, and enterprise management is expected to improve.